# Suzhou Yilian Bio-Pharmaceutical Co

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/suzhou-yilian-bio-pharmaceutical-co

- Industry: Biotechnology
- Headquarters: China
- Total disclosed funding: $124M
- Latest round: Series B (Mar 14, 2022)
- Investors on record: 7

## About

Founded in 2020 by CEO Xue Tongtong and based in China, Suzhou Yilian Bio-Pharmaceutical Co Ltd, also known as Yilian Biotechnology, operates as a biotechnology company that develops antibody conjugated drugs (ADC). The firm raised funding of CNY 350 million in March 2021 from  Xingze Capital, Qiming Venture Capital, and Loyal Valley Capital.

Yilian Biotechnology develops antibody conjugated drugs to treat cancer cells and release a toxic drug into the cancer cell.

The firm plans to use its Series A funds towards the development of its antibody conjugated drug (ADC) product pipeline and the establishment of a new conjugated drug research and development platform.

## Funding rounds

- Series B, Mar 14, 2022, $70M — Legend Capital, Qiming Venture Partners, Honghui Capital, LYFE Capital, Zhengxingu Capital
- Series A, Mar 1, 2021, $54M — Qiming Venture Partners, Loyal Valley Capital, Apricot Capital

## Investors

- Qiming Venture Partners (https://capitalatlas.ai/funds/qiming-venture-partners) — Series A, Series B
- Loyal Valley Capital (https://capitalatlas.ai/funds/loyal-valley-capital) — Series A
- Apricot Capital (https://capitalatlas.ai/funds/apricot-capital) — Series A
- Legend Capital — Series B
- Honghui Capital — Series B
- LYFE Capital — Series B
- Zhengxingu Capital — Series B